Vanda Pharmaceuticals Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $146.0m $165.1m $193.1m $227.2m $248.2m $268.7m $254.4m $192.6m $198.8m $216.1m
Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization $64.8m $58.1m $65.6m $74.6m $23.4m $25.6m $24.3m $14.8m $11.3m $13.0m
Operating expenses:
Operating Income (Loss) ($18.6m) ($16.9m) $21.7m $22.8m $27.2m $42.2m $6.3m ($14.0m) ($40.7m) ($151.2m)
Additional Financial Items
Amortization of Intangible Assets $10.9m $1.8m $1.5m $1.5m $1.5m $1.5m $1.5m $2.1m $7.3m $7.0m
Income (Loss) from Continuing Operations before Income Taxes, Domestic ($18.1m) ($15.7m) $25.1m $28.8m $31.7m $42.2m $11.2m $6.2m ($23.0m) ($138.9m)
Other Income $665k $1.5m $3.6m $6.2m $4.4m $199k $5.0m $20.3m $17.7m $12.5m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $42.4m $11.3m $6.3m ($22.9m) ($138.6m)
Net Income (Loss) Attributable to Parent ($18.0m) ($15.6m) $25.2m $115.6m $23.3m $33.2m $6.3m $2.5m ($18.9m) ($220.5m)
Earnings Per Share, Basic ($0.41) ($0.35) $0.50 $2.17 $0.43 $0.60 $0.11 $0.04 ($0.33) ($3.74)
Earnings Per Share, Diluted ($0.41) ($0.35) $0.48 $2.11 $0.42 $0.58 $0.11 $0.04 ($0.33) ($3.74)
Weighted Average Number of Shares Outstanding, Basic 43.4m 44.7m 50.9m 53.1m 54.4m 55.5m 56.5m 57.4m 58.1m 58.9m
Weighted Average Number of Shares Outstanding, Diluted 43.4m 44.7m 53.0m 54.8m 55.2m 56.9m 57.0m 57.6m 58.1m 58.9m
Research and Development Expense $29.2m $38.5m $43.6m $48.6m $55.6m $75.4m $85.8m $76.8m $74.4m $109.3m
Selling, General and Administrative Expense $99.8m $123.8m $105.8m $129.7m $140.5m $124.0m $136.5m $112.9m $146.4m $238.0m
Costs and Expenses $164.6m $182.0m $171.4m $204.4m $220.9m $226.5m $248.1m $206.6m $239.4m $367.3m
Income Tax Expense (Benefit) $104k $136k $138k ($86.5m) $8.3m $9.2m $5.0m $3.8m ($4.0m) $81.8m